OTCMKTS:UCBJF - UCB Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$77.95 0.00 (0.00 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$77.95
Today's Range$77.95 - $77.95
52-Week Range$76.6550 - $94.30
Average Volume170 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$4.55 billion
Cash Flow$3.3585 per share



Next Earnings DateN/A
OptionableNot Optionable

UCB (OTCMKTS:UCBJF) Frequently Asked Questions

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

What is the consensus analysts' recommendation for UCB?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for UCB.

Has UCB been receiving favorable news coverage?

Media coverage about UCBJF stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. UCB earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of UCB's key competitors?

What other stocks do shareholders of UCB own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UCB investors own include Airbus (AIR), Daimler (DDAIF), Radius Health (RDUS), ABLYNX NV/ADR (ABLX) and Circassia Pharmaceuticals (CIR).

Who are UCB's key executives?

UCB's management team includes the folowing people:
  • Jean-Christophe Tellier, Chief Executive Officer & Executive Director
  • Charl van Zyl, Chief Operating Officer
  • Detlef Thielgen, Chief Financial Officer & Executive Vice President
  • Iris Löw-Friedrich, Chief Medical Officer & Executive Vice President
  • Dhavalkumar Patel, Chief Scientific Officer & EVP

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $77.95.

What is UCB's official website?

The official website for UCB is http://www.ucb.com.

How can I contact UCB?

UCB's mailing address is 60 ALLEE DE LA RECHERCHE, BRUSSELS C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]

MarketBeat Community Rating for UCB (OTCMKTS UCBJF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote "Outperform" if you believe UCBJF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Diversification

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel